- Cryoport as a preferred partner for Lonza in the transport and delivery of patient tissues on a global basis
- Partnership incorporates Cryoport’s Cryoportal® Logistics Management Platform, SmartPak II™ Condition Monitoring System and Cryoport’s unique Chain of Compliance™ for regulatory solutions.
- Partnership builds on the recently announced partnership between Lonza and Vineti with an aim to provide cell and gene therapy developers with a fully integrated delivery solutions including manufacturing, supply chain orchestration and logistics, globally
Quote from Alberto Santagostino, SVP Head of Cell & Gene Technologies, Lonza Pharma & Biotech:
"The Lonza-Cryoport collaboration is an enabling part of a wider goal for Lonza to create a network of strategic partnerships and capabilities that enable seamless vein-to-vein delivery of cell and gene therapies for its customers and their patients. There is no doubt that this partnership enables us to provide a best-in-class solution to cell and gene therapy companies for manufacturing and supply chain services, allowing us to provide a fully integrated solution that reduces risk and increases transparency."
Quote from Jerrell Shelton, CEO, Cryoport:
“Clinical trial activity in the cell and gene therapy sector is rapidly growing as biopharmaceutical companies discover new ways to harness regenerative therapies and combat illnesses. As more and more of these therapies approach commercialization, there is strengthening demand for reliable, integrated outsourced manufacturing and distribution solutions. Our partnership agreement with Lonza, an internationally-renowned supplier to the pharma and biotech markets, will improve effectiveness, efficiency and safety throughout the cell and gene therapy manufacturing process by integrating our temperature-controlled supply chain solutions with Lonza’s manufacturing services.”
Basel, Switzerland and Irvine, California, November 5 2019 – Lonza (SWX: LONN) and Cryoport, Inc. (NASDAQ: CYRX) (“Cryoport”), announced today their partnership in the cell and gene therapy field and across Lonza's 'vein-to-vein' delivery network. As a part of this commitment, Lonza announced Cryoport as its preferred partner in the transport and delivery of patient tissues on a global basis, with the continued goal of seamless service for Lonza's customers and their patients. Lonza and Cryoport will work to remove the supply chain hurdles faced by developers of personalized therapeutics -- including autologous therapies, matched-allogeneic therapies, and personalized cancer vaccines -- as they prepare for the commercial launch of their respective therapies.
Lonza’s network of cell and gene therapy facilities spans the US, Europe and Asia and serves both clinical and commercial customers globally. Cryoport currently supports over 413 clinical trials and 3 commercial therapies in the regenerative medicine space and operates in over 100 countries around the world. Integrating Cryoport’s logistics andbioservices solutions with Lonza’s manufacturing services and expertise will ensure a trusted and seamless supply chain and drive efficiencies in delivering innovative medicines to patients.
The goal of the partnership is to provide fully integrated solutions including, but not limited to, co-location of manufacturing, bioservices and distribution facilities to improve and enhance responsiveness and optimized product workflow, automated data management providing integrated data entry, and process optimization that reduces risk, increases transparency and improves certainty.
Cryoport’s logistics system aims to provide Lonza’s clients with reliable and comprehensive delivery solutions through its advanced technologies, Global Supply Chain Network and dedicated scientists, technicians and supporting teams of professionals. Beyond Cryoport’s proprietary Cryoport Express® Shippers, this partnership incorporates Cryoport’s Cryoportal® Logistics Management Platform and SmartPak II™ Condition Monitoring System, which brings to the market an integrated IT solution that provides risk mitigation and Cryoport’s unique Chain of Compliance™ for regulatory solutions.